This week, we dive into a sudden and seismic regulatory shift in Argentina. ANMAT's newly issued Resolution 785/2025 has introduced strict data localization and cybersecurity audit requirements for all Software as a Medical Device (SaMD) and connected devices, sending shockwaves through the industry. This episode breaks down the immediate implications for foreign manufacturers, who now face a tight 180-day deadline to overhaul their data infrastructure. We explore the strategic challenges posed by this new regulation, from the technical complexities of data migration to the uncertainty surrounding the list of approved local auditors. This is a must-listen for any MedTech company operating in or planning to enter the Argentinian market, providing a clear-eyed look at the new reality of digital protectionism in Latin America and what it takes to maintain compliance and market access. A specific case we discuss involves a leading European AI radiology software provider. Their platform relies on centralized servers in Brazil, and they now face the daunting and costly task of migrating their entire operation to a local Argentinian data center within 180 days. This unexpected mandate threatens to disrupt their services for existing hospital clients and could derail their growth strategy in the region. Key questions for this episode: - What are the exact requirements of ANMAT's new Resolution 785/2025? - How does the data localization mandate impact cloud-based SaMD and IoT devices? - What are the first three steps your company must take to assess its compliance risk? - Why are even well-established products with existing registrations in Argentina at risk? - How can you find and qualify a local data hosting partner that meets ANMAT's new stringent standards? - What specific cybersecurity documentation must be added to your technical dossier for submission? - Is this new Argentinian rule a blueprint for future regulations in other major LATAM markets? Struggling with sudden regulatory shifts in LATAM? Pure Global offers end-to-end regulatory consulting for MedTech and IVD companies, combining local expertise with advanced AI to streamline global market access. From acting as your local representative in Argentina to developing a new regulatory strategy for data compliance, we ensure you maintain your market presence without disruption. Contact us at info@pureglobal.com or visit https://pureglobal.com/ to learn more.

This week, we dissect a game-changing regulatory shift in Latin America's largest market. Brazil's ANVISA has just proposed a new fast-track approval process for AI-driven medical software, promising to slash market entry timelines for devices already approved by agencies like the FDA. But a closer look reveals a complex new challenge that could catch even the most prepared companies off guard. Imagine you're a global MedTech company with an FDA-cleared diagnostic AI. You see the 'fast-track' news from Brazil and plan for a quick launch. But your planned submission is suddenly non-compliant, citing a new, demanding annex on data traceability and cybersecurity specific to the Brazilian population that your initial regulatory package never accounted for. This is the hidden reality companies will now face. What you'll learn in this episode: - What is ANVISA's new proposed fast-track for AI medical devices? - Why is the new data governance requirement a hidden barrier for foreign manufacturers? - How do these proposed Brazilian rules differ from standard FDA or Health Canada requirements? - Could this 'fast-track' pathway actually delay market entry for unprepared companies? - What immediate steps should you take to assess your AI's training data for compliance? - Which specific local data protection protocols (LGPD) are now integrated into regulatory clearance? - How can this change be leveraged to build a stronger, more defensible market position in Brazil? Don't let regulatory surprises derail your LATAM expansion. Pure Global offers end-to-end regulatory consulting, combining local expertise with advanced AI tools to streamline market access in Brazil and over 30 other markets. We help you navigate complex changes like ANVISA's new AI rules, ensuring your technical dossier is compliant from day one. Contact us at info@pureglobal.com or visit https://pureglobal.com/ to secure your market presence.

Brazil's regulatory agency, ANVISA, has just redefined the future of digital health in Latin America with its new, comprehensive framework for AI-powered Software as a Medical Device (SaMD). This landmark regulation introduces a stricter risk classification system and new requirements for algorithm validation and cybersecurity, directly impacting any MedTech company looking to enter or grow in the region's largest market. This episode of LATAM MedTech Insights provides a crucial analysis of these changes. We uncover what the new four-tiered risk system means for your product, how to manage the lifecycle of your AI algorithms under the new rules, and why aligning with Brazil's data privacy laws is now more critical than ever. This isn't just a regulatory update. it's a strategic shift that will influence the entire LATAM region. **Case Study:** Imagine your AI-powered diagnostic tool, which has been operating in a regulatory gray area, is suddenly reclassified as a high-risk device under the new ANVISA framework. You now face urgent demands for more extensive clinical data, a formal algorithm change protocol, and stricter cybersecurity measures, potentially delaying your market access by months. Are you prepared to meet this new, higher standard. **Key Takeaways:** * What are the most significant changes in ANVISA's new SaMD regulation. * How does Brazil's new AI framework compare to the FDA and EU MDR standards. * Why might your SaMD's risk classification change overnight in Brazil. * What specific cybersecurity vulnerabilities is ANVISA now targeting. * Has the Brazilian market become more challenging or more predictable for foreign SaMD companies. * How will this decision impact regulatory trends in other LATAM markets like Mexico and Colombia. * What are the immediate next steps your regulatory team must take to ensure compliance. Navigating these regulatory shifts requires local expertise and a global strategy. Pure Global offers end-to-end regulatory consulting for MedTech and IVD companies, using advanced AI and data tools to streamline global market access. We help you turn regulatory complexity into a competitive advantage. To secure your position in the evolving Latin American market, contact us at info@pureglobal.com or visit us at https://pureglobal.com/.

This week on LATAM MedTech Insights, we're diving into a groundbreaking regulatory shift in Brazil. For years, launching a clinical trial in Latin America's largest market was a high-risk gamble due to unpredictable and lengthy approval processes. Now, everything has changed. A new Clinical Research Statute is dismantling these old barriers, aiming to slash approval times and make Brazil a global hub for MedTech innovation. We explore the concrete changes to the ethics review system and what this means for international companies that had previously put their Brazilian market entry plans on hold. A U.S. MedTech startup with a novel cardiovascular device had to shelve its plans to enter Brazil because of the dreaded 18-month approval delays, which threatened their investment timeline. Now, the new law presents a clear, predictable path to starting their clinical trial in under six months, completely changing their strategic calculus for the LATAM region. This Episode’s Key Takeaways: - Why was Brazil’s old clinical trial system a major roadblock for MedTech innovators? - How exactly does the new Clinical Research Statute reduce approval timelines? - What is the role of the new INEP ethics board, and how does it differ from the old system? - Are the responsibilities for trial sponsors now easier to manage in Brazil? - What immediate steps should a foreign MedTech company take to leverage this new regulation? - Is Brazil poised to become the new leader for clinical research in Latin America? - What are the hidden risks or remaining challenges in this new regulatory environment? At Pure Global, we offer end-to-end regulatory consulting solutions to help MedTech and IVD companies navigate complex markets like Brazil. We combine local expertise with advanced AI and data tools to streamline global market access, from initial strategy and technical dossier submission to post-market surveillance. Let us be your local representative and strategic partner in over 30 markets worldwide. To turn these insights into your market success story, contact us at info@pureglobal.com or visit https://pureglobal.com/.

This episode of LATAM MedTech Insights dives deep into the most significant regulatory shift in the region's largest market: Brazil. We explore ANVISA's new regulations, RDC 751/2022 for medical devices and RDC 830/2023 for IVDs, which align Brazil's framework more closely with international standards like the EU MDR. This is a critical update for any MedTech company looking to enter or expand its footprint in Latin America. We unpack what this harmonization means in practical terms. Consider this: a medical device company with CE marking for its product previously faced a complex, 18-month process to reformat its entire technical dossier for Brazil. Today, that same dossier can be leveraged to gain market access in a fraction of the time and cost. This episode explains how you can capitalize on this change and avoid common pitfalls during the transition. Key Takeaways: * How does Brazil's new RDC 751/2022 fundamentally change the market entry strategy for your medical device? * What is the critical June 1, 2024 deadline for IVD manufacturers under RDC 830/2023 and what must be done? * Can your existing EU or FDA technical documentation be used for a submission in Brazil now? * How does Brazil's regulatory shift compare to changes happening in Mexico and Colombia? * What are the key differences between the old 'cadastro' system and the new 'notificação' pathway? * Why is having an expert local representative in Brazil more crucial than ever under these new rules? * What are the most common mistakes companies make when transitioning their legacy products to the new regulations? Pure Global offers end-to-end regulatory consulting solutions for MedTech and IVD companies. We combine local expertise with advanced AI and data tools to streamline your global market access, from initial strategy to post-market surveillance. To navigate the complexities of the LATAM market, contact us at info@pureglobal.com or visit https://pureglobal.com/.

In this episode of LATAM MedTech Insights, we explore why a one-size-fits-all approach to entering the Latin American medical technology market is a recipe for failure. The region is not a monolith but a collection of unique countries, each with its own distinct regulatory, economic, and healthcare systems. Success depends on moving beyond surface-level data and leveraging deep market intelligence. We dissect how granular market briefs provide the critical insights needed to build a winning go-to-market strategy. We contrast the opportunities in a market like Colombia, which heavily relies on imports, with the complex regulatory hurdles of a giant like Brazil. This episode will show you how the right data can illuminate your path, save you from costly mistakes, and give you a decisive competitive advantage. A Tale of Two Markets: Imagine targeting Colombia, where an 80% import dependency for medical devices signals a ready-made demand for your product. Now, picture Brazil, where your market entry is halted before it begins because you were unaware of the mandatory pre-submission GMP inspection by ANVISA. This single regulatory detail could delay your launch by over a year and add tens of thousands to your budget. Which path would you rather take? Key Takeaways: * Why is treating LATAM as a single market the most common strategic error? * What does Colombia's 80% import dependency really mean for your sales strategy? * How can Brazil's ANVISA pre-registration requirements completely alter your budget and timeline? * Beyond market size, what are the most critical data points a market brief must contain? * How does deep market intelligence inform your choice between direct entry and a distributor model? * What hidden regulatory hurdles could derail your launch in promising markets? * How can you leverage existing international approvals to potentially fast-track your LATAM entry? * What economic indicators should you monitor that directly impact medical device reimbursement? At Pure Global, we transform this critical data into actionable strategy. We offer end-to-end regulatory consulting solutions for MedTech and IVD companies, combining local expertise with advanced AI to streamline your global market access. Stop guessing and start strategizing. Contact us at info@pureglobal.com or visit https://pureglobal.com/ to learn how we can help you succeed in Latin America and beyond.

Brazil's MedTech market offers immense opportunity, but its regulatory body, ANVISA, demands flawless execution. A fragmented approach, where different teams handle registration and post-market compliance, often leads to costly delays and strategic dead ends. This episode explores why an integrated strategy is non-negotiable for success. We break down the four pillars of Brazilian MedTech regulation: correct device classification, meticulous technical documentation in Portuguese, the critical choice of a Brazil Registration Holder (BRH), and robust post-market surveillance. Learn how these elements are interconnected and why managing them under one expert team provides a significant competitive advantage in this complex market. **A cautionary tale:** Imagine spending over a year and thousands of dollars to prepare your device registration, only to discover that the distributor you appointed as your local representative (BRH) has decided to partner with a competitor. Because they legally own your registration license, you have completely lost market access and must start the entire process from scratch, giving your competition a two-year head start. **In this episode, you will learn:** * Why is Brazil's four-class risk system more nuanced than it appears? * What are the most common documentation mistakes that lead to ANVISA rejections? * How can the choice of your Brazil Registration Holder (BRH) make or break your entire LATAM strategy? * Are you truly in control of your device registration if your distributor is your BRH? * What specific post-market surveillance activities does ANVISA require beyond simple adverse event reporting? * Why is having a single, integrated team for registration and post-market support a competitive advantage in Brazil? * What is BGMP certification and why is it non-negotiable for higher-risk devices? At Pure Global, we offer end-to-end regulatory solutions for MedTech and IVD companies. Our integrated approach combines local Brazilian expertise with advanced AI tools to streamline market access, from initial strategy to post-market surveillance. Contact us to learn how our unified team can de-risk and accelerate your entry into the Brazilian market. Email us at info@pureglobal.com or visit https://pureglobal.com/.

In this episode of LATAM MedTech Insights, we dive deep into the unique regulatory landscape of Colombia, a pivotal market for any device manufacturer looking to enter Latin America. We uncover how INVIMA's dual-track system offers a strategic gateway for MedTech companies that know how to leverage it. We explore the powerful "automatic registration" pathway for low-risk devices that can get your product to market and generating revenue faster than you think. We also break down the complexities and extended timelines associated with the rigorous pre-approval process for high-risk technologies, and how to plan for them effectively. A Case for Strategy: Imagine trying to launch your entire device portfolio, from simple monitors to complex implants, into a new continent at once. The pain point is the immense upfront cost and the years of waiting for approvals before seeing a single dollar in return. One company flipped this challenge on its head. They launched their Class I device in Colombia in just a few months, using the immediate cash flow to fund the lengthy, data-intensive registration for their groundbreaking Class III product. This is how a regulatory landscape becomes a competitive advantage. This episode's key takeaways: 1. What is Colombia's "automatic registration" and which specific devices qualify? 2. How can a fast-track for low-risk products actually fund your entire LATAM expansion? 3. What are the most common documentation pitfalls that lead to rejection in an "automatic" submission? 4. How do you prepare a technical dossier for a high-risk Class III device that satisfies INVIMA's stringent review? 5. Why is a staggered, portfolio-based market entry strategy essential for success in Colombia? 6. How does your Colombian approval act as a potential stepping stone for other LATAM markets? 7. What are the critical roles and responsibilities of a local Legal Representative in the INVIMA process? At Pure Global, we specialize in transforming complex regulatory landscapes into clear, actionable market access strategies. Our teams of local experts, powered by advanced AI and data tools, offer end-to-end solutions for MedTech and IVD companies. Whether you are navigating Colombia's INVIMA for the first time or expanding across the continent, we streamline your path to market. Ready to build your LATAM strategy? Contact us at info@pureglobal.com or visit https://pureglobal.com/.

In this episode of LATAM MedTech Insights, we demystify the complex process of medical device registration in Argentina. We provide a detailed guide on navigating the requirements of the national regulatory authority, ANMAT, from appointing a local registration holder to preparing a compliant technical dossier in Spanish. We break down the critical steps and common pitfalls that can lead to costly delays and rejections. Learn why your choice of a local partner can make or break your market access strategy and how your existing international approvals, like CE or FDA, fit into the Argentinian framework. We share a real-world case where a simple oversight in device grouping strategy tripled a company's registration costs and delayed market entry by a full year, highlighting the financial and strategic importance of local know-how. Key questions answered in this episode: - Why is selecting the right Argentina Registration Holder (ARH) your most critical first step? - What are the specific Spanish language requirements for your technical file that most companies miss? - How can a proper device family strategy cut your ANMAT submission costs and timeline? - What is the one common document error that causes the longest delays with ANMAT's review clock? - Are your existing CE or FDA approvals enough to guarantee a smooth registration in Argentina? - What are the realistic timelines you should expect for ANMAT approval for different device classes? - How can you avoid having your registration "held hostage" by a local commercial partner? At Pure Global, we provide end-to-end regulatory solutions for MedTech companies seeking to enter or expand in Latin America. Our local experts in Argentina, combined with our advanced AI tools, streamline the ANMAT registration process, from strategy and dossier preparation to post-market compliance. Let us be your dedicated partner in unlocking this key market. Contact us at info@pureglobal.com or visit https://pureglobal.com/ to learn more.

Peru's MedTech market offers immense growth opportunities, but entry is strictly controlled by its regulatory authority, DIGEMID. A critical step for any foreign manufacturer is appointing a local representative, known as a Peru Registration Holder. This isn't just a formality—it's a foundational strategic decision that dictates your control over your own products in the country. In this episode, we explore why the common shortcut of letting a distributor hold your product registration can lead to significant business risks, including a complete loss of market access. We'll walk through the strategic advantages of appointing an independent, professional representative to ensure you maintain full control over your commercial strategy and long-term success in Peru. Here is a situation we explore: Imagine your medical device has been selling in Peru for two years. Your relationship with your distributor, who also holds your DIGEMID registration, has broken down. You decide to switch partners, only to discover the distributor refuses to transfer the registration. They legally own your access to the market. You are now faced with a devastating choice: stay with an underperforming partner or pull your product and start the costly, year-long registration process all over again. This is a real and preventable crisis. Key Takeaways: 1. What is the precise function of a "Peru Registration Holder" for DIGEMID? 2. Why is it a significant risk to let your distributor be your registration holder? 3. What are the legal implications of who owns your product registration in Peru? 4. How does an independent local representative provide crucial commercial flexibility? 5. What happens to your market access if your relationship with your distributor-holder ends? 6. What are the key steps in the DIGEMID registration process that a local representative handles? 7. How does having a dedicated representative help in navigating post-market surveillance in Peru? At Pure Global, we specialize in demystifying complex regulatory landscapes like Peru's. We provide independent, expert local representation, ensuring you retain full control over your assets while we handle the complexities of DIGEMID. Secure your market access and build a flexible, scalable LATAM strategy. Contact us to learn more at info@pureglobal.com or visit our website at https://pureglobal.com/.

This episode of LATAM MedTech Insights dives into one of the most stable and attractive regulatory environments in Latin America: Colombia. We explore how INVIMA, the national regulatory authority, offers a clear and predictable pathway for medical device manufacturers, standing in contrast to the complexities found elsewhere in the region. We specifically focus on the significant strategic advantage of Colombia's ten-year registration validity for most medical devices. This episode unpacks how this long-term approval cycle can reduce administrative burdens, lower costs, and enable companies to focus on sustainable market growth instead of constant regulatory upkeep. A real-world pain point we address is the risk of losing market access. Imagine a company thriving in Colombia, only to realize their local partner missed the critical 90-day renewal submission deadline with INVIMA. This oversight forces their product off the market, jeopardizing distributor contracts and revenue streams, all of which could have been avoided with proactive regulatory management. In this episode, you will learn the answers to key questions: 1. Why is a 10-year registration validity a game-changer for your MedTech commercial strategy in LATAM? 2. What is the single most important deadline you cannot miss when renewing your INVIMA registration? 3. How does a reliable local representative in Colombia provide value beyond just submitting paperwork? 4. What are the common pitfalls that cause companies to lose their market access in Colombia, even with a long validity period? 5. How can you leverage your stable Colombian registration to plan for expansion into other Andean markets? 6. What key documents should you be preparing years in advance of your 10-year renewal? Pure Global offers end-to-end regulatory consulting solutions for MedTech and IVD companies, combining local expertise with advanced AI and data tools to streamline global market access. We act as your local representative in Colombia and over 30 other markets, ensuring your registrations are managed proactively and your market presence is secure. To learn more, contact us at info@pureglobal.com or visit https://pureglobal.com/.

Brazil, Latin America's largest MedTech market, is implementing a mandatory Unique Device Identification (UDI) system, with a critical deadline for high-risk devices looming in mid-2025. This change, mandated by ANVISA's RDC 591/2021, requires immediate action from manufacturers to ensure their products remain on the market. This episode of LATAM MedTech Insights breaks down the essential steps for preparing for Brazil's UDI rollout. We explore the unique challenge where device labeling is required before the official government database (SIUD) is fully active, creating significant operational hurdles. We'll provide a clear roadmap for what your company needs to do right now to avoid costly disruptions to your Brazilian operations. **Case Study Highlight:** Imagine your company manufactures a Class IV cardiovascular stent. You have all the clinical approvals, but your product is suddenly blocked from entering Brazil on July 11, 2025. The reason is a non-compliant label. Your team waited for final guidance on the UDI database, but the fixed labeling deadline passed, halting your sales and forcing an expensive, rushed relabeling project. This scenario is avoidable, and this episode explains how. **What You'll Learn (本期干货):** * What is the crucial compliance date in 2025 that affects all Class IV medical devices in Brazil? * Why do you need to change your product labels now, even if the SIUD database isn't live? * How do ANVISA's UDI data requirements differ from those of the US FDA or European MDR? * What are the first three steps every manufacturer should take to begin their UDI implementation project? * What is the essential role of a Brazil Registration Holder (BRH) in this new process? * How can you manage the artwork and logistical challenges of a full labeling redesign? * What are the most common pitfalls companies face when preparing for a new UDI system? At Pure Global, we offer end-to-end regulatory consulting to help MedTech and IVD companies navigate complex market access challenges like Brazil's UDI implementation. We combine local expertise with advanced AI tools to streamline your path to compliance. For support with regulatory strategy, technical dossier submission, or local representation in Brazil, contact us at info@pureglobal.com or visit https://pureglobal.com/.

This week, we dissect a game-changing regulatory shift in Latin America's largest market. Brazil's ANVISA has just launched a new resolution for Software as a Medical Device (SaMD), creating an unprecedented fast-track pathway for innovative digital health products. This move promises to slash approval times and attract global investment. But there's a catch. While the new "fast-track" leverages existing international approvals, it also imposes stricter, more sophisticated requirements on technical documentation, cybersecurity, and clinical data relevance for the Brazilian population. This episode explores how savvy MedTech companies can seize this opportunity while avoiding the hidden pitfalls that could lead to rejection. **Case Study:** A European AI-driven diagnostic software company, already holding a CE mark, has been planning its entry into Brazil. The new ANVISA resolution seems like a golden ticket to bypass the historically long review times. But will their existing technical file be enough? Are their cybersecurity protocols compliant with Brazil's specific data laws? We break down the critical gaps they must fill to turn this opportunity into a market reality. **Key Questions Answered:** - What are the specific criteria to qualify for ANVISA's new SaMD fast-track pathway? - How can you leverage your existing FDA or CE marking approval for a faster Brazilian registration? - What are the top three new documentation requirements that most companies will overlook? - Why is adapting your clinical data to Brazilian demographics now non-negotiable? - What specific cybersecurity vulnerabilities is ANVISA now scrutinizing more than ever? - How has the role of the Brazil Registration Holder (BRH) evolved from a legal requirement to a strategic necessity? Pure Global offers end-to-end regulatory consulting solutions for Medical Technology (MedTech) and In-Vitro Diagnostic (IVD) companies, combining local expertise with advanced AI and data tools to streamline global market access. Contact Pure Global at info@pureglobal.com or visit us at https://pureglobal.com/.

In this episode of LATAM MedTech Insights, we demystify the complex world of Brazil's medical device regulations under ANVISA. We explore the critical differences between the faster 'Notificação' pathway for low-risk devices and the intensive 'Registro' full-review process for high-risk products, revealing why your strategy for one won't work for the other. This episode is for any MedTech company that sees Brazil as a key market but is concerned about the regulatory hurdles. We break down the real-world implications of each pathway, from documentation requirements to the formidable challenge of the Brazilian Good Manufacturing Practices (BGMP) audit, ensuring you understand exactly what it takes to succeed. Key questions answered in this episode: * Why is Brazil's ANVISA a two-speed system for medical devices? * What is the critical difference between the *Notificação* and *Registro* pathways? * Could your Class II device from the US or EU require a full, lengthy review in Brazil? * What is the BGMP audit, and why is it often the biggest hurdle for high-risk device manufacturers? * How can a local Brazil Registration Holder (BRH) make or break your market entry strategy? * Are you underestimating the documentation requirements for a "simple" notification? * How does proper device classification at the start save you months, or even years, in delays? Pure Global offers end-to-end regulatory consulting to streamline your global market access. We combine local expertise in over 30 markets with advanced AI to get your MedTech and IVD products to market efficiently. To develop your tailored regulatory strategy for Brazil or beyond, contact us at info@pureglobal.com or visit https://pureglobal.com/.

In this episode of LATAM MedTech Insights, we explore the groundbreaking regulatory reforms in Mexico that are set to accelerate market access for medical device manufacturers. We break down the new COFEPRIS abbreviated pathway, which leverages approvals from other international regulatory bodies to streamline the registration process. This shift marks a significant opportunity for MedTech and IVD companies to enter one of Latin America's largest markets faster than ever before. We discuss the practical implications of these homologation reforms, detailing how leveraging existing clearances from authorities like the European Union can drastically cut down approval timelines and costs, turning a previously lengthy process into a strategic advantage. Consider a medical device company with a CE-marked product that was previously facing a potential 18-month review cycle with COFEPRIS. The pain of this delay meant losing critical market share to competitors already established in Mexico. We explore how, under the new abbreviated pathway, this company could now potentially achieve registration in under six months, transforming their entire market entry strategy for the LATAM region. Key Takeaways: * What specific international approvals does Mexico's COFEPRIS now recognize for its abbreviated pathway? * How does the new COFEPRIS-04-050 procedure fundamentally differ from the traditional, full review process? * What are the critical documentation requirements for leveraging a foreign approval under the homologation reform? * What common mistakes can lead to delays or rejections even when using the new accelerated route? * Why is appointing a qualified local registration holder in Mexico more important than ever with these new changes? * Does the abbreviated pathway apply equally to all classes of medical devices and IVDs? * How can you strategically assess if your product portfolio is a good fit for Mexico's new regulatory environment? At Pure Global, we specialize in transforming these complex regulatory shifts into clear, actionable market access strategies. Our team of local experts in Mexico, combined with our advanced AI and data tools, ensures your submission for the new abbreviated pathway is seamless, compliant, and efficient. Don't let regulatory complexity slow your expansion into Latin America. Contact us at info@pureglobal.com or visit https://pureglobal.com/ to get started.

Mexico presents a golden opportunity for MedTech companies, but its regulatory body, COFEPRIS, has a critical requirement: all foreign manufacturers must appoint a local Mexico Registration Holder (MRH). This entity doesn't just submit your paperwork; they legally own your product registration, a detail that can make or break your business in the region. This episode of LATAM MedTech Insights dives deep into the strategic importance of this decision. We explore the significant risks of appointing a distributor as your MRH and how this can lead to a loss of market control, and we outline the powerful advantages of partnering with an independent, professional registration holder to secure your investment and ensure long-term business flexibility. Here is a real-world example. A promising diagnostics company spent nearly two years achieving COFEPRIS approval, only to realize their underperforming distributor, who they appointed as their MRH, legally owned their market access. When they tried to switch to a better commercial partner, the distributor refused to transfer the registration, effectively holding their multi-million dollar market entry hostage. Key Questions from this Episode: 1. Who legally owns your MedTech registration in Mexico? 2. What are the hidden risks of appointing your distributor as your COFEPRIS Registration Holder? 3. How can you change commercial partners in Mexico without losing your registration and starting over? 4. What is the difference between a Registration Holder and a local distributor? 5. Why is an independent MRH considered the gold standard for market entry? 6. What clauses must be in your MRH agreement to protect your company? 7. How does the MRH role impact your post-market surveillance obligations? At Pure Global, we specialize in securing your market access. We act as your independent, professional Registration Holder in Mexico and over 30 markets worldwide, ensuring you always remain in control of your valuable registrations. Our end-to-end regulatory solutions, powered by local expertise and advanced AI, are designed to protect your assets and streamline your global expansion. Contact us at info@pureglobal.com or visit https://pureglobal.com/ to learn more.

In this episode of LATAM MedTech Insights, we dissect the complex regulatory pathways for two key medical device categories in Latin America: surgical instrument sets and electrosurgical units. We explore the fragmented nature of LATAM regulations, moving beyond generalities to offer specific, actionable insights. We delve into the critical "family grouping" strategies required by Brazil's ANVISA for large instrument sets and contrast them with the requirements of Mexico's COFEPRIS. For active devices, we uncover the often-overlooked mandatory electrical safety certifications, like INMETRO in Brazil, that can halt a product launch in its tracks, even after clinical approval seems within reach. A common pain point for manufacturers is seeing their state-of-the-art electrosurgical unit, with CE Marking and FDA clearance, get stuck for an extra nine months before entering the massive Brazilian market. The reason? They were unaware that their existing electrical safety test reports were not enough and that mandatory, in-country INMETRO testing was required from the start. This oversight leads to unforeseen costs, major timeline delays, and loss of first-mover advantage. Key questions answered in this episode: - How can I register a surgical set with over 100 instruments in Brazil without filing 100 separate applications? - What is the critical non-medical certification required for electronic devices in Brazil that many companies miss? - Why is a local "Registration Holder" non-negotiable for market access in countries like Mexico and Brazil? - How do the registration requirements for a simple scalpel differ from a complex electrosurgical generator in Colombia? - Why isn't my FDA 510(k) or CE Mark a direct passport for market entry in Latin America? - What are the realistic timelines for getting a medical device approved by ANVISA versus COFEPRIS? - How can a proactive regulatory strategy for LATAM save hundreds of thousands of dollars in potential delays? At Pure Global, we specialize in navigating these complexities. We offer end-to-end regulatory consulting solutions for MedTech and IVD companies, acting as your local registration holder and managing the entire submission process with our in-country experts and advanced AI tools. Don't let regulatory hurdles block your expansion. Contact us at info@pureglobal.com or visit https://pureglobal.com/ to learn how we can streamline your market access.

The Latin American market for anesthesia machines and equipment is expanding rapidly, driven by significant investments in both public and private healthcare infrastructure. This growth presents a massive opportunity for MedTech manufacturers, but it comes with a formidable challenge: a highly complex and fragmented regulatory environment that can stop even the most prepared companies in their tracks. In this episode, we unpack the practical realities of entering this lucrative market. We go beyond the surface-level data to explore the specific, detailed requirements of key regulatory bodies like Brazil's ANVISA and Mexico's COFEPRIS. We'll discuss the critical differences in procurement strategies between elite private hospitals and large-scale public health systems and reveal the common pitfalls that lead to costly delays and rejections. Here is a real-world scenario. A promising European MedTech company developed a cost-effective anesthesia ventilator perfect for the public hospital systems in Brazil. They invested heavily in a market launch, anticipating a quick approval based on their CE Mark. However, their submission was stalled for over two years due to an unexpected and lengthy audit requirement of their manufacturing facility by ANVISA, a detail buried deep in the regulations. This delay allowed a local competitor to capture the market share they were targeting. Key Takeaways This Episode: 1. Why is a 'one-size-fits-all' regulatory strategy for Latin America guaranteed to fail? 2. What is the single biggest non-documentary hurdle for registering Class III devices like anesthesia machines in Brazil? 3. How do Mexican regulators use FDA or Health Canada approvals, and what is the crucial catch that many companies miss? 4. Why might your sales strategy for a hospital in São Paulo be completely different from one for a public tender in Colombia? 5. What are the most common and costly mistakes in technical dossier preparation for ANVISA and COFEPRIS? 6. Is it possible to leverage a single registration process for multiple LATAM markets? 7. How has the post-pandemic shift impacted the demand for specific features in anesthesia equipment? 8. What role does a local, in-country registration holder play, and why is choosing the right one so critical? At Pure Global, we transform these complex regulatory challenges into clear market access strategies. Our end-to-end solutions for MedTech and IVD companies combine deep local expertise in over 30 markets with advanced AI and data tools to streamline your global expansion. Don't let regulatory hurdles dictate your growth potential. Contact us at info@pureglobal.com or visit https://pureglobal.com/ to secure and accelerate your market access in Latin America.

In this episode of LATAM MedTech Insights, we explore the immense opportunities and significant regulatory challenges of bringing blood glucose monitoring devices to the Latin American market. We uncover the specific demands of key regulatory bodies like Brazil's ANVISA, Mexico's COFEPRIS, and Argentina's ANMAT. We break down the complex, country-specific requirements that often trip up manufacturers. Imagine launching your state-of-the-art continuous glucose monitor in Brazil, only to be rejected by ANVISA after a year-long review because of an overlooked electrical safety certification. This common pitfall highlights the critical need for local expertise, a topic we dissect with real-world examples to help you avoid costly delays and gain a competitive edge. What you will learn in this episode: - What are the key regulatory differences between Brazil's ANVISA, Mexico's COFEPRIS, and Argentina's ANMAT? - How can a US FDA approval fast-track your device registration in Mexico? - What is the most common reason for ANVISA submission delays for blood glucose monitors? - Why is a certified Spanish translation more than just a language requirement for Argentina's ANMAT? - What is a Brazil Registration Holder, and why is it legally essential for market access? - How do local clinical data requirements impact CGM device approvals in the region? - What are the critical post-market surveillance responsibilities you cannot ignore in these markets? At Pure Global, we provide end-to-end regulatory consulting to help MedTech and IVD companies seamlessly access over 30 global markets, including the complex LATAM region. By combining our deep local expertise with advanced AI tools, we streamline your path to market. Let us be your local representative and strategic partner. Contact us at info@pureglobal.com or visit https://pureglobal.com/ to learn more.

In this episode of LATAM MedTech Insights, we delve into the booming orthopedic surgical implant market across Latin America. We uncover why a successful market-entry strategy requires more than just a great product and existing international approvals. We explore the complex and fragmented regulatory landscapes of key countries like Brazil, Mexico, and Colombia, highlighting the critical differences that can make or break your expansion plans. We share a cautionary tale of a premier German knee implant company, holding a valid CE mark, that faced a two-year delay in entering the Mexican market. Their mistake was assuming their European clinical data and technical file would suffice. They were caught off guard by COFEPRIS's requirement for in-country biocompatibility testing and their local sales distributor's inability to navigate the intricate submission process, leading to a costly and frustrating stalemate. Key questions from this episode: -Why is Brazil's ANVISA known to reject submissions that are easily approved by the FDA or EMA? -What are the biggest risks of appointing a commercial distributor as your legal registration holder in Mexico? -How can you leverage your existing approvals to potentially speed up registration in Colombia? -What are the most common labeling mistakes that lead to rejection by Argentina's ANMAT? -How do post-market surveillance requirements for orthopedic implants differ between Brazil and Mexico? -Are there hidden costs associated with improper Spanish and Portuguese technical translations in your dossier? -Is it possible to build a core technical file that can be adapted for multiple LATAM countries? -What specific local clinical data do authorities demand for high-risk orthopedic devices? At Pure Global, we specialize in transforming these regulatory hurdles into market opportunities. We offer end-to-end solutions for MedTech companies, combining deep local expertise in over 30 markets with advanced AI tools to streamline your global market access. Let us be your strategic partner in navigating the complexities of LATAM. Contact us at info@pureglobal.com or visit https://pureglobal.com/ to learn more.

In this episode of LATAM MedTech Insights, we delve into the rapidly expanding but notoriously complex market for cardiac monitoring and ECG devices in Latin America. We uncover why the region's high demand, fueled by demographic shifts and a growing healthcare sector in countries like Brazil, Mexico, and Argentina, presents both a massive opportunity and a significant challenge for global MedTech manufacturers. We explore the fragmented regulatory maze, moving beyond theory to discuss the practical realities of dealing with powerful agencies like Brazil's ANVISA and Mexico's COFEPRIS. We share a detailed case study of a European company whose launch of an innovative wearable ECG patch was delayed by 18 months due to a critical oversight in their Brazilian submission, illustrating how a small gap in local knowledge can lead to major commercial setbacks and loss of market share. 本期干货: - Why is Brazil’s ANVISA one of the most difficult regulatory bodies for cardiac device approval? - What are the three most common mistakes companies make when submitting technical files to COFEPRIS in Mexico? - How is the rise of telemedicine in Colombia changing the rules for market entry? - What specific in-country testing is required for ECG devices in Argentina that isn't required for a CE mark? - How can you design a single regulatory strategy to efficiently target Brazil, Mexico, and Colombia simultaneously? - What are the hidden costs associated with not having an experienced local registration holder? - How do reimbursement policies in public versus private healthcare sectors impact your product's profitability? The Latin American market holds immense potential, but navigating its regulatory and commercial landscape requires deep, localized expertise. At Pure Global, we transform these complex challenges into clear market access strategies. With our local experts in over 30 countries and advanced AI-driven data tools, we streamline the entire process from initial strategy to post-market surveillance. Don't let regulatory hurdles dictate your growth. Contact us to build your customized pathway into the LATAM market at info@pureglobal.com or visit us at https://pureglobal.com/.

In this episode of LATAM MedTech Insights, we delve into the burgeoning market for digital X-ray and radiographic equipment in Latin America. We explore the powerful growth drivers, from government healthcare modernization projects in Brazil to the booming private medical sector in Mexico, revealing why this region is a key target for global MedTech innovators. However, this opportunity is guarded by a maze of complex and fragmented regulations. We uncover the specific challenges of navigating distinct regulatory bodies like Brazil's ANVISA, Mexico's COFEPRIS, and Argentina's ANMAT. Imagine your company has a groundbreaking portable X-ray device ready to launch. You target Brazil and Mexico, only to find your market entry stalled for months. ANVISA demands a complete dossier overhaul in Portuguese, while COFEPRIS requires a separate, equally complex process in Spanish. This common scenario leads to mounting costs and lost market share, a critical pain point we address. What you'll learn in this episode: - Why is the LATAM digital X-ray market a key area for growth? - What are the crucial differences between registering a device with ANVISA in Brazil and COFEPRIS in Mexico? - How does the requirement for a local Brazil Registration Holder (BRH) affect your market entry strategy? - What common documentation and labeling mistakes lead to registration delays in countries like Colombia and Argentina? - Why is a 'one-size-fits-all' regulatory approach destined to fail in Latin America? - What role do public healthcare systems, like Brazil's SUS, play in driving demand for new radiographic equipment? - How can you transform a fragmented regulatory landscape into a streamlined, multi-market access strategy? At Pure Global, we turn these complex regulatory challenges into a streamlined pathway to market access. We offer end-to-end solutions, acting as your local representative and using advanced AI tools to manage technical dossiers and submissions across multiple LATAM markets simultaneously. Stop letting regulatory hurdles block your growth. Contact us at info@pureglobal.com or visit https://pureglobal.com/ to learn more.

In this episode of LATAM MedTech Insights, we dissect the burgeoning market for endoscopic imaging systems in Latin America. We explore the massive opportunities in key countries and expose the intricate regulatory hurdles that often lead to costly delays and market access failures for international MedTech companies. We move beyond theory to discuss the practical realities of registering advanced medical devices in this high-growth region. From Brazil's demanding ANVISA documentation and INMETRO certification to Mexico's unique COFEPRIS requirements and the critical need for a local legal representative, we provide actionable insights for manufacturers. Learn how to avoid common pitfalls and strategize for a successful launch across multiple LATAM markets. **Case Study:** A German MedTech innovator developed a state-of-the-art endoscopic camera with AI-driven diagnostic capabilities. They targeted Brazil's advanced private hospital network, but their launch was stalled for over a year. Their fatal error was assuming their CE marking would streamline the process. They were unprepared for ANVISA's demand for local clinical data to validate the AI algorithm on a Brazilian population and failed the initial INMETRO electrical safety inspection, forcing a product redesign and restarting a lengthy certification process. **Key Takeaways:** * Why might your existing clinical data be rejected by Brazil's ANVISA, and what can you do about it? * What are the critical differences between appointing a distributor versus an independent entity as your legal representative in Mexico? * How can INMETRO certification in Brazil become a hidden cause for significant product launch delays? * What specific dossier and labeling requirements for Colombia's INVIMA often get overlooked by foreign manufacturers? * How do you build a regulatory strategy that allows for a single, efficient submission process across multiple LATAM countries like Peru and Argentina? * What are the most common mistakes in translating technical documentation for Spanish and Portuguese-speaking regulatory bodies? **Unlock LATAM with Pure Global.** Navigating the fragmented regulatory systems of Latin America is a significant challenge. At Pure Global, we transform this complexity into a clear path to market. Our integrated solution combines in-country experts in Brazil, Mexico, Colombia, and beyond with advanced AI tools to streamline your registration process. We provide end-to-end support, from regulatory strategy and technical dossier submission to acting as your local legal representative and managing post-market surveillance. Don't let regulatory hurdles block your growth. Contact us at info@pureglobal.com or visit https://pureglobal.com/ to accelerate your entry into the LATAM MedTech market.

Last week, Brazil's ANVISA unleashed a pivotal update for Software as a Medical Device (SaMD) with its new resolution, RDC 992/2025. While appearing to align with international standards, this new regulation introduces complex cybersecurity and data privacy requirements tied specifically to Brazil's LGPD law, creating unexpected hurdles for global manufacturers. In this episode of LATAM MedTech Insights, we dissect the fine print of ANVISA's new rules. We explore the immediate operational impacts, from mandatory local data protection officers to new clinical data requirements for AI-driven software, and discuss the strategic adjustments companies must make to maintain or gain market access in Latin America's largest market. Case Study: Imagine you're a US-based scaleup with a groundbreaking AI diagnostic tool. Your EU MDR and FDA clearances are in hand, and Brazil is your next target. Suddenly, your registration is stalled. Why? Your application didn't address specific LGPD data transfer protocols and your designated data officer isn't based in Brazil. This is the new reality—a costly and time-consuming roadblock that a standard regulatory checklist would have missed. Key Takeaways: 1. What are the three 'hidden' requirements in ANVISA's new SaMD rule that most foreign companies will miss? 2. How does Brazil's LGPD law now directly impact your medical device's technical file? 3. Is your current cybersecurity plan sufficient for the new Brazilian standards? 4. Why might your existing AI/ML validation data be rejected by ANVISA? 5. What's the new mandatory role you might need to hire in Brazil to keep your SaMD on the market? 6. How does this update affect legacy SaMD products already registered in Brazil? 7. What are the critical deadlines you cannot afford to ignore over the next six months? Navigating the evolving regulatory landscape in Latin America requires more than just a checklist; it demands localized, expert strategy. At Pure Global, we offer end-to-end regulatory consulting for MedTech and IVD companies, combining deep local expertise with advanced AI tools to streamline your global market access. We act as your local representative, manage your technical dossier, and ensure continuous compliance. Don't let regulatory surprises derail your expansion. Contact us at info@pureglobal.com or visit https://pureglobal.com/ to secure your market presence.

In this episode of LATAM MedTech Insights, we explore the lucrative yet complex market for infusion pumps in Latin America. As hospitals across the region upgrade their technology for better patient outcomes, the demand for advanced medication delivery systems is at an all-time high. However, gaining market access is a formidable challenge, with each country's regulatory agency—from Brazil's ANVISA to Mexico's COFEPRIS—imposing unique and stringent requirements. We uncover the specific hurdles manufacturers face, from lengthy manufacturing audits to critical translation errors that can derail a product launch. For instance, a leading MedTech company faced a nine-month delay in Mexico because their user manual's Spanish translation was not adapted to local clinical terminology, forcing a complete resubmission to COFEPRIS and a costly delay in revenue. Key Takeaways in this Episode: - Why does Brazil's ANVISA require an in-person audit of your factory, and how long could it delay your market entry? - What is the single most common submission mistake that leads to rejection by Mexico's COFEPRIS? - How can your existing FDA or CE Mark approval accelerate your registration in Colombia? - Why is having a local, in-country representative a non-negotiable for MedTech registration in LATAM? - What are the documentation requirements for a high-risk Class III device like an infusion pump? - How is the shift from standard IV drips to "smart pumps" creating new opportunities in the region? - What are the key differences between the 'Registro' and 'Cadastro' pathways in Brazil? Pure Global offers end-to-end regulatory consulting solutions for MedTech and IVD companies, combining local expertise with advanced AI to streamline global market access. We act as your local representative and registration holder, developing efficient pathways for regulatory approval across more than 30 countries. To overcome these challenges and unlock the LATAM market, contact us at info@pureglobal.com or visit https://pureglobal.com/.

In this episode of LATAM MedTech Insights, we move beyond the headlines of the pandemic to uncover the real state of the respiratory device market in Latin America. The urgent rush for ventilators has subsided, leaving behind a complex landscape of equipment surplus, shifting clinical needs, and formidable regulatory barriers. We explore how the focus is moving from emergency ICU equipment to long-term solutions for chronic conditions like COPD and sleep apnea, creating new opportunities for agile MedTech companies. Imagine you are a MedTech innovator with a cutting-edge respiratory device, ready to tap into the burgeoning Brazilian market. Your launch is stalled for months because the regulatory body, ANVISA, rejects your submission on a technicality that was buried in local-language guidelines. This common but costly scenario is the focus of our discussion, highlighting how navigating the unique regulatory maze of each LATAM country is the key to success. What you'll learn in this episode: 1. Why is the post-pandemic ventilator surplus a multi-million dollar opportunity for service and maintenance companies? 2. How is the demand for home-care respiratory devices changing the market in Mexico and Argentina? 3. What are the top 3 regulatory mistakes foreign companies make when submitting to ANVISA in Brazil? 4. Why is securing a local registration holder in Colombia so difficult and what are the risks? 5. Are local manufacturers a credible threat to established international brands? 6. How can you leverage your existing FDA or CE mark for a faster pathway in countries like Peru and Chile? 7. What specific clinical data do LATAM regulators want to see for respiratory devices? 8. How is telehealth integration becoming a key differentiator for new products in the region? At Pure Global, we transform these regulatory complexities into clear market access strategies. We provide end-to-end regulatory consulting and act as your official local representative in over 30 markets, including Brazil, Mexico, and Colombia. Our combination of local experts and advanced AI tools streamlines the submission process to authorities like ANVISA and COFEPRIS, getting your products to market faster. Don't let bureaucracy block your expansion. Contact us at info@pureglobal.com or visit https://pureglobal.com/ to get started.

In this episode of LATAM MedTech Insights, we explore the rapidly growing but complex market for hemodialysis machines and dialyzers in Latin America. We uncover the key drivers behind the region's multi-billion dollar renal care industry, focusing on the specific regulatory, logistical, and commercial hurdles in key countries like Brazil, Mexico, and Colombia. We examine real-world scenarios where manufacturers have faced significant delays and strategic pivots. For example, a European dialyzer company with full CE marking was stalled for over a year trying to enter Brazil, simply because they were unprepared for the mandatory in-person ANVISA inspection of their overseas facility. This single oversight cost them millions in potential revenue and market share. We break down why such situations are common and how they can be avoided. Key Takeaways: - Are you prepared for the unique Brazilian GMP certification process required by ANVISA before your product can be sold? - How does your market entry strategy for Mexico account for COFEPRIS's specific dossier and labeling requirements? - What are the key differences in reimbursement models between Colombia and Argentina that could impact your sales strategy? - How can you build a resilient supply chain to handle customs and distribution challenges across diverse LATAM territories? - Is partnering with local dialysis clinics a better strategy than direct sales for your technology? - What are the post-market surveillance requirements you must maintain to ensure long-term compliance in the region? - How can you leverage your existing registrations to fast-track entry into smaller but growing markets like Peru and Chile? Navigating the complexities of the Latin American MedTech market is a challenge. At Pure Global, we offer end-to-end regulatory consulting solutions, combining local expertise with advanced AI to streamline global market access. We act as your local representative and registration holder, managing everything from initial strategy to post-market surveillance. Contact us to accelerate your growth in Latin America at info@pureglobal.com or visit https://pureglobal.com/.

In this episode of LATAM MedTech Insights, we demystify the medical device registration process in Peru by taking a close look at the foundational regulation: Supreme Decree Nº 016-2011-SA. We explore how the national authority, DIGEMID, uses a risk-based classification system and what this means for your specific device. We break down the critical requirements that often create barriers for foreign manufacturers, including the mandatory appointment of a Peruvian Registration Holder (PRH) and the specific documentation needed for your submission dossier. This episode provides essential, practical insights for any MedTech company considering Peru as their next market. A Real-World Challenge: Imagine your company has a CE-marked Class III device ready for the LATAM market. You find a distributor in Peru, but your shipment is stopped at customs. Why? Because you didn't appoint a Peruvian Registration Holder (PRH) and your technical dossier wasn't submitted to DIGEMID according to the specific rules of Supreme Decree 016-2011-SA. This episode breaks down how to avoid this costly and time-consuming mistake. What you'll learn in this episode: 1. What is the primary role of Supreme Decree 016-2011-SA in Peru's MedTech landscape? 2. How does Peru's risk classification system (Class I-IV) impact your registration strategy? 3. Why is a Peruvian Registration Holder (PRH) mandatory for all foreign manufacturers? 4. What is a Certificate of Free Sale, and why is it critical for your application to DIGEMID? 5. What are the most common documentation and language pitfalls for companies entering Peru? 6. How long is a Sanitary Registration valid, and what does the renewal process involve? 7. What are the key differences in requirements for low-risk versus high-risk devices? At Pure Global, we specialize in transforming these regulatory hurdles into market opportunities. We offer end-to-end solutions, from acting as your local Peruvian Registration Holder to compiling and submitting your technical dossiers with our advanced AI tools. Stop letting complex regulations slow down your LATAM expansion. Contact us at info@pureglobal.com or visit https://pureglobal.com/ to streamline your market access.

In this episode of LATAM MedTech Insights, we provide a detailed analysis of Chile's Resolution Exenta No. 1618/2020, a landmark regulation that established a strict technovigilance framework for medical devices. We dissect the specific reporting obligations, mandatory timelines, and the critical role of the in-country legal representative. This session moves beyond theory to explore the practical challenges and common mistakes foreign manufacturers face when dealing with the Chilean health authority (ISP). We unpack the nuances of identifying trends from seemingly minor incidents and explain how failure to comply can lead to significant regulatory penalties and loss of market access. **What You’ll Learn:** * What is the precise definition of a "reportable adverse event" under Chilean law? * Are you aware of the crucial 10-day vs. 30-day reporting deadlines? * How can a series of minor device malfunctions escalate into a major compliance issue? * Why is your local Chilean representative absolutely essential for successful technovigilance reporting? * What are the most common reporting errors that foreign companies make with the ISP? * How can you differentiate between an isolated incident and a reportable trend? * What are the documentation expectations for an initial adverse event report versus a final one? Pure Global offers end-to-end regulatory consulting for MedTech and IVD companies, combining local expertise with advanced AI to streamline global market access. Let us be your local representative and navigate complex regulations for you. Contact us at info@pureglobal.com or visit https://pureglobal.com/ to learn more.

In this episode of LATAM MedTech Insights, we dissect the crucial updates to Brazil's medical device regulations, specifically ANVISA's RDC 497/2021 and the recent amendment RDC 850/2024. We explore how these resolutions have fundamentally changed the administrative process for obtaining and renewing the essential Brazilian Good Manufacturing Practice (B-GMP) certificate. We uncover why the recent extension of B-GMP validity from two to four years makes a flawless submission more critical than ever. We'll walk you through a real-world case study of a diagnostic device manufacturer that faced a three-month market lockout due to minor administrative errors in their renewal application, highlighting the costly pitfalls of navigating these new standardized procedures without expert local knowledge. Key questions answered in this episode: 1. What is the true impact of RDC 497/2021 on my existing Brazilian device registration? 2. How did the recent RDC 850/2024 amendment change the game for B-GMP certificate renewals? 3. What are the most common and costly administrative pitfalls when submitting documents to ANVISA's Solicita system? 4. Why is a simple document codification error now enough to get my entire submission rejected? 5. How far in advance should I begin my B-GMP renewal process to avoid market disruption? 6. What specific steps can I take to ensure my technical dossier is compliant with the latest requirements? 7. How can I turn these regulatory updates into a strategic advantage for my company in Brazil? At Pure Global, we transform regulatory complexity into market access. Our team of local experts, powered by advanced AI tools, offers end-to-end solutions for MedTech and IVD companies in over 30 markets, including Brazil. From initial strategy to post-market surveillance, we act as your local representative to ensure your products reach the market efficiently and remain compliant. Don't let administrative hurdles block your growth in Latin America. Contact us at info@pureglobal.com or visit https://pureglobal.com/ to learn more.

A response indicating that the requested information could not be found.

This episode of LATAM MedTech Insights offers a detailed guide to registering your medical device in Colombia, focusing on the foundational regulation, Decree 4725 of 2005. We break down the essential requirements set by Colombia's regulatory authority, INVIMA, providing manufacturers with a clear roadmap for successful market entry into one of Latin America's most dynamic healthcare markets. Imagine your company has developed an innovative Class IIb diagnostic device. You are ready to tap into the Colombian market, but your submission is rejected by INVIMA. The reason is a failure to properly appoint a local legal representative and your Instructions for Use (IFU) were not translated into Spanish according to specific regulatory standards. This single oversight delays your launch by over six months, allowing competitors to establish their footprint. This episode provides the details to avoid such costly mistakes. Key Takeaways: 1. What are the four distinct risk classifications for medical devices under Decree 4725 of 2005? 2. Does your product qualify for the faster "automatic registration" pathway in Colombia? 3. Why is a Certificate of Free Sale (CFS) from your device's country of origin an absolute must-have for your INVIMA submission? 4. What are the legal responsibilities of the mandatory in-country representative in Colombia? 5. What are the specific Spanish-language labeling requirements that can lead to an application's rejection? 6. How long is a medical device registration valid in Colombia, and what should you know about the renewal process? 7. What key technical documents are required by INVIMA for a Class IIb or Class III device submission? At Pure Global, we specialize in navigating these complex regulatory landscapes. We offer end-to-end solutions, from market strategy and local representation to AI-powered technical dossier preparation, ensuring your path to the Colombian market is efficient and successful. For expert guidance, contact us at info@pureglobal.com or visit us at https://pureglobal.com/.

In this episode of LATAM MedTech Insights, we demystify the seemingly simple but highly nuanced process of renewing medical device registrations in Argentina. We take a close look at the specific requirements outlined in ANMAT's Disposition 2318/2002, focusing on the critical 90-day submission deadline and the legally binding "sworn declaration." We explore the common pitfalls that can lead to costly delays and even market withdrawal. A minor change in your product's documentation or manufacturing process, considered insignificant in other markets like the EU or USA, could completely invalidate your renewal application in Argentina, forcing you into a lengthy and expensive new registration process. **What You'll Learn:** - What is the absolute deadline for submitting your renewal application to ANMAT, and what are the consequences of missing it? - How does ANMAT's definition of a "significant change" differ from that of the FDA or European Notified Bodies? - Why could a simple update to your Instructions for Use (IFU) derail your entire renewal? - What specific information is included in the "sworn declaration," and what are the legal risks involved? - When is a renewal not an option, forcing you to file for a completely new registration? - What is the critical role of the Authorized Local Representative (ARL) in ensuring a smooth renewal process? Struggling to keep up with the diverse and evolving regulatory requirements across Latin America? At Pure Global, we offer end-to-end regulatory consulting solutions for MedTech and IVD companies. We combine local expertise with advanced AI and data tools to streamline global market access, acting as your local representative in over 30 markets, including Argentina. Let us help you ensure your products remain compliant and accessible. Contact us today at info@pureglobal.com or visit https://pureglobal.com/ for a consultation.

This episode of LATAM MedTech Insights provides a detailed analysis of Mexico's mandatory Good Manufacturing Practices (GMP) standard, NOM-241-SSA1-2021. We explore the critical requirements for medical device manufacturers, importers, and distributors operating in Mexico, focusing on the pillars of a compliant Quality Management System (QMS), risk management, and supply chain control. We break down what COFEPRIS, Mexico's health authority, looks for during an audit and why simply being ISO 13485 certified is not enough. This episode is essential for any MedTech company looking to leverage Mexico's manufacturing advantages and access one of the largest markets in Latin America. We also look ahead to the upcoming changes with the 2025 version of the standard, helping you stay ahead of the regulatory curve. Consider this real-world scenario: a U.S. MedTech scale-up invests millions in a state-of-the-art manufacturing facility in Jalisco, aiming to supply the entire LATAM region. However, their market launch is halted after a COFEPRIS audit. The reason? Their risk management files were deemed static, and their supplier validation for a critical component sourced from Asia lacked the specific traceability data required by NOM-241, jeopardizing their entire investment and market-entry strategy. What You'll Learn: 1. Why is NOM-241 a mandatory gateway to the Mexican market and not just a guideline? 2. What are the core pillars of a Quality Management System that COFEPRIS auditors scrutinize? 3. How does NOM-241's approach to technovigilance impact the entire product lifecycle? 4. What are the most common documentation gaps that lead to GMP compliance failures in Mexico? 5. Are your supplier qualification processes robust enough for the standard's strict requirements? 6. How can you prepare your facility for the upcoming changes in the 2025 version of NOM-241? 7. Why might your existing quality certifications be insufficient for gaining approval in Mexico? 8. What specific risk management activities must be continuously updated to maintain compliance? Navigating complex local regulations like NOM-241 is critical for success. At Pure Global, we offer end-to-end regulatory consulting for MedTech companies, combining deep local expertise in over 30 markets with advanced AI tools to streamline your global market access. From initial regulatory strategy to acting as your local representative, we ensure your path to compliance is clear and efficient. Don't let regulatory hurdles block your expansion. Contact us at info@pureglobal.com or visit https://pureglobal.com/ to learn more.

This week, we dissect the immediate fallout from ANVISA's surprise regulatory shift in Brazil. While the move towards EU MDR alignment was expected, a hidden clause mandating local usability studies for high-risk devices has caught many international MedTech firms by surprise, threatening to delay launches and inflate budgets. We explore the specifics of the new RDC 987/2025 resolution and what it means for companies who previously relied on their CE marking for a smoother entry into Latin America's largest market. This episode is a must-listen for regulatory affairs professionals, product managers, and executives focused on global expansion. A leading German cardiac stent company had its Brazilian launch plan finalized, with its budget approved and timeline set. Last week’s ANVISA announcement instantly invalidated their strategy. Now, they're facing an unexpected nine-month delay and an unbudgeted six-figure cost for a mandatory local study they never saw coming. Key questions from this episode: - Does ANVISA's new rule make your existing technical file obsolete for Brazil? - What are the hidden costs and timeline impacts of the mandatory in-country usability studies? - How can you leverage your existing data to potentially streamline this new local requirement? - Could this regulatory shift in Brazil signal a trend for other LATAM markets? - Is your local representative in Brazil equipped to manage these new complex clinical requirements? - What steps should you take today to de-risk your 2026 LATAM launch plans? Navigating sudden regulatory changes requires deep local expertise and a proactive strategy. At Pure Global, we offer end-to-end regulatory consulting, acting as your local representative in over 30 markets, including Brazil. We use advanced AI and data tools combined with on-the-ground expertise to streamline global market access and ensure you're always ahead of the curve. Don't let regulatory surprises derail your growth. Contact us at info@pureglobal.com or visit https://pureglobal.com/ to secure your market presence.

In this episode of LATAM MedTech Insights, we explore the intricate details of Mexico's medical device labeling standard, NOM-137-SSA1-2008. As one of Latin America's largest MedTech markets, Mexico presents a huge opportunity, but access is strictly controlled by its regulatory body, COFEPRIS. We break down the most common mistakes foreign manufacturers make, from language requirements to the specific data that must be present on your packaging. Learn how to navigate the nuances of primary versus secondary labels, the correct way to use supplementary stickers, and why your local distributor's information is a critical component for avoiding customs delays. Case Study: Imagine your multi-million dollar shipment of medical devices, fully approved in the US and EU, gets stuck indefinitely in Mexican customs. The reason? A single line of missing text on a small sticker. We explore a real-world scenario where a simple labeling mistake involving the distributor's address cost a company months of delays and significant financial loss—a completely avoidable problem. Key questions answered in this episode: 1. Why is simply translating my existing label into Spanish not enough for COFEPRIS?. 2. What specific information about my Mexican distributor must be on the packaging?. 3. How do labeling rules differ for primary sterile packaging versus the outer box?. 4. Can I use stickers to add Mexican requirements, and what are the rules to avoid rejection?. 5. What is a Sanitary Registration number and where must it appear on my label?. 6. Are there upcoming changes to NOM-137 that I need to be aware of right now?. 7. How must the 'Hecho en' (Made in) information be formatted to ensure compliance?. Pure Global offers end-to-end regulatory consulting for MedTech and IVD companies, combining local expertise with advanced AI to streamline global market access. Let us help you navigate the complexities of markets like Mexico. Contact us at info@pureglobal.com or visit https://pureglobal.com/ to learn more.

In this episode of LATAM MedTech Insights, we demystify the mandatory INMETRO certification for electro-medical devices in Brazil. We break down the critical requirements of Ordinance 384/2020, a regulation that serves as a vital gatekeeper to one of Latin America's most significant markets. We'll guide you through the conformity assessment process, from selecting a Certification Body to undergoing factory audits and product testing. We explore the distinct roles of ANVISA and INMETRO, clarifying how they work together and what manufacturers must do to satisfy both. We highlight common pitfalls, such as assuming your existing FDA or CE mark documentation is sufficient, and provide actionable insights to ensure a smoother path to certification. This episode is essential listening for any MedTech company planning to sell electro-medical devices in Brazil. A real-world example. A promising European MedTech scale-up developed an innovative portable ultrasound device. They secured CE marking and assumed their technical file was robust enough for global markets. Upon targeting Brazil, they were blocked for months. Their challenge was not the quality of their device, but their failure to understand the nuances of INMETRO's audit process under Ordinance 384/2020, which required specific traceability protocols not emphasized in their EU audit. This oversight led to costly delays and a scramble for local regulatory expertise. Key Takeaways This Episode: 1. What is the fundamental difference between ANVISA's market registration and INMETRO's conformity assessment? 2. How do you select the right INMETRO-accredited Certification Body for your device? 3. What are the three most common documentation mistakes that lead to delays in the certification process? 4. What can you expect during the mandatory on-site factory audit, regardless of your global location? 5. Are INMETRO certificates truly valid indefinitely, and what is the catch? 6. Why is the INMETRO Conformity Identification Seal more than just a label? 7. How can you leverage your Brazil registration strategy for other markets in Latin America? At Pure Global, we transform these complex regulatory hurdles into clear pathways for market access. Our team of local experts, powered by advanced AI and data tools, offers end-to-end solutions for MedTech and IVD companies. From initial regulatory strategy and technical dossier submission to acting as your local representative, we streamline your entry into over 30 global markets, including Brazil. Don't let regulatory complexities be a barrier to your growth. Contact us at info@pureglobal.com or visit https://pureglobal.com/ to learn how we can accelerate your global expansion.

This episode of LATAM MedTech Insights unpacks the significant changes introduced by Brazil's new medical device regulation, ANVISA RDC 751/2022. We explore how this new framework moves Brazil towards harmonization with international standards, particularly the EU MDR, and what this means for global MedTech companies. We break down the practical impact of the updated risk classification system and the new technical dossier structure. This shift is a game-changer for manufacturers, promising to reduce complexity, time, and cost when entering Latin America's largest market. **Case Study:** Imagine a US-based MedTech scale-up with an innovative patient monitoring system that has already achieved CE marking in Europe. They view Brazil as a critical growth market but are hesitant due to its reputation for complex, unique regulatory requirements. Their primary pain point is the fear of investing months of work and significant capital to completely re-author their technical documentation just for one market. RDC 751 directly solves this by allowing them to leverage their existing EU MDR-compliant dossier, turning a potential roadblock into a streamlined entry point. **Key Takeaways From This Episode:** * How does the new four-tier risk classification system under RDC 751 affect your market entry strategy for Brazil? * What specific sections of your existing EU MDR or FDA technical file can now be repurposed for an ANVISA submission? * Are there changes to the requirements for Brazilian Good Manufacturing Practice (B-GMP) certification? * How does the new regulation impact the need for and the role of a local Brazil Registration Holder? * What are the updated pathways for low-risk versus high-risk devices, and how do they affect your launch timeline? * How will ANVISA's alignment with the IMDRF framework change your future global registration planning? * What are the key considerations for post-market surveillance under the new RDC 751? At Pure Global, we specialize in turning regulatory complexity into market opportunity. With our local expertise in Brazil and advanced AI tools, we offer end-to-end solutions to streamline your ANVISA registration process under RDC 751. Let us be your partner in unlocking the potential of the LATAM market. Contact us at info@pureglobal.com or visit https://pureglobal.com/ to learn more.

Brazil's MedTech market is one of the largest in Latin America, but its regulatory landscape, governed by ANVISA, can seem complex. Many SaMD companies overestimate the time and difficulty of market entry, missing out on significant opportunities. This episode demystifies the process for Class II Software as a Medical Device. We reveal the streamlined 'notificação' pathway, a simplified notification process that can lead to market approval in as little as 30 days. We walk through a real-world example of a dermatology AI app, detailing how proper preparation of the technical dossier and leveraging local expertise led to a rapid and successful market launch, avoiding common delays that can stall companies for months. What you'll learn in this episode: - What is the difference between ANVISA's 'notificação' and 'registro' pathways? - How can a Class II SaMD be approved in under 30 days in Brazil? - What are the essential documents required for a successful SaMD submission? - Why is a Brazil Registration Holder (BRH) mandatory for foreign companies? - What are the most common mistakes that cause delays in ANVISA's review? - How does regulation RDC 751/2022 impact your device classification? - What specific cybersecurity information does ANVISA expect for a SaMD? At Pure Global, we specialize in transforming complex regulatory challenges into clear, actionable market access strategies. With our end-to-end solutions combining local expertise in over 30 countries and advanced AI tools, we help MedTech and IVD companies accelerate their global expansion. Contact us to streamline your entry into the LATAM market. Email us at info@pureglobal.com or visit us at https://pureglobal.com/.

Colombia's MedTech market is one of the fastest-growing in Latin America, offering significant opportunities for global manufacturers. However, navigating its regulatory landscape, managed by INVIMA, presents a unique challenge that can make or break your market entry strategy: the mandatory local legal representative. This episode of LATAM MedTech Insights unpacks this critical requirement. We explore why simply appointing your in-country distributor can be a catastrophic mistake, leading to a loss of control over your own product registration and effectively locking you out of the market. We'll detail the precise role of a legal representative and how choosing an independent partner ensures your business remains agile and in control of its own destiny. Imagine this scenario. You've successfully registered your medical device in Colombia through your distributor. After two years of building the brand, you decide to switch to a new commercial partner for better market penetration. That's when you get the bad news. Your distributor refuses to transfer the registration, which is legally in their name. Your only option is to start the entire expensive and time-consuming registration process from scratch, leaving you unable to sell your product for over a year. In this episode, you will learn the answers to these critical questions: - Why does INVIMA mandate a local representative for all foreign medical device companies? - What are the hidden legal and commercial risks of appointing your distributor as your representative? - How can you permanently lose the rights to your own device registration in Colombia? - What is the crucial difference between a commercial partner and a professional regulatory representative? - What are the key responsibilities a local representative handles beyond just submitting paperwork? - How does an independent representative give you the power to change your sales strategy without regulatory delays? - What specific qualities should you look for when selecting a local representative in Colombia? At Pure Global, we act as your professional, independent legal representative in Colombia and over 30 markets worldwide. We secure your registrations in your name, giving you the freedom to build the best commercial strategy for your products. Don't let a simple mistake lock you out of a key market. Contact us at info@pureglobal.com or visit https://pureglobal.com/ to learn how we provide a secure and efficient pathway into Latin America.

In this episode of LATAM MedTech Insights, we explore the essential labeling and language regulations for Software as a Medical Device (SaMD) in Mexico. We unpack the specific requirements set by the national regulatory body, COFEPRIS, and highlight the critical importance of Spanish language localization for a successful market entry. We discuss a common pitfall through a case study: an innovative SaMD company faces a costly six-month delay in their COFEPRIS application. The reason? While all their documents were translated, the software's user interface, including simple menus and error messages, was left in English—a critical oversight that made their product non-compliant. This episode details how to avoid this and other regulatory hurdles. Key questions answered in this episode: - What is the single most important language requirement for medical device software in Mexico? - Which specific Mexican Official Standard (NOM) governs all labeling rules? - Does the language requirement apply to the software's user interface and error messages? - What specific information must be included in the electronic label of a SaMD? - How can a simple localization mistake lead to significant delays and costs with COFEPRIS? - Where must labeling information be placed for software that is downloaded versus distributed on physical media? - Why is treating translation as a final step a major risk for your market access strategy? At Pure Global, we specialize in streamlining global market access for MedTech companies. Our team combines local expertise with advanced AI tools to manage your entire regulatory lifecycle, from initial strategy and technical dossier submission to post-market surveillance. Let us be your local representative in Mexico and over 30 other markets. Contact us at info@pureglobal.com or visit https://pureglobal.com/ to learn more.

In this episode of LATAM MedTech Insights, we dissect the complex world of SaMD registration in Brazil. We go beyond the surface-level question of certifications and explore the strategic nuances that can define your success in Latin America's largest market. We explain why simply having an ISO 13485 certificate, the global standard for quality management, is not enough to get your software approved by ANVISA. We uncover the critical role of Brazilian Good Manufacturing Practices (BGMP) and reveal how the Medical Device Single Audit Program (MDSAP) can be your most powerful tool. Learn how leveraging MDSAP can slash your time-to-market from years to months, giving you a significant competitive advantage. Imagine you've developed a groundbreaking AI diagnostic tool. You have your ISO 13485 certificate and are ready to launch in Brazil. You submit to ANVISA, only to be told the wait for a mandatory quality system inspection is over two years long. Your entire commercialization plan is on hold. Meanwhile, your competitor, who also has ISO 13485 but strategically invested in an MDSAP certification, uses it to bypass the inspection queue. They are on the market in six months, capturing key clients while you are still waiting. This episode tells you how to be the competitor who wins. This episode's key takeaways: - Why is an ISO 13485 certificate insufficient for your ANVISA SaMD submission? - What exactly is Brazilian BGMP and which device classes require certification before market entry? - How can the MDSAP program reduce your time-to-market in Brazil by over 18 months? - Are lower-risk SaMD exempt from quality system requirements in Brazil? - What is the difference between a *notificação* and a *registro* pathway for SaMD? - Which specific Brazilian regulation, RDC 657/2022 or RDC 751/2022, governs your software's requirements? - How does a weak regulatory strategy create a two-year competitive disadvantage? At Pure Global, we specialize in turning regulatory hurdles into market opportunities. We offer end-to-end regulatory consulting for MedTech and IVD companies, combining local LATAM expertise with advanced AI tools to streamline your global market access. Let us be your local representative and build the most efficient regulatory pathway for your technology. Contact us at info@pureglobal.com or visit https://pureglobal.com/.

In this episode of LATAM MedTech Insights, we demystify the process of registering a foreign-made AI medical device in Mexico. As one of Latin America's largest and most promising markets, Mexico presents a significant opportunity for MedTech innovators. However, its regulatory body, COFEPRIS, has unique requirements that can stall market entry if not navigated correctly. We explore why COFEPRIS treats AI and Software as a Medical Device (SaMD) differently than other global agencies and reveal the single most effective strategy for expedited approval: the Equivalency Agreement. Learn how leveraging your existing FDA, Health Canada, or Japan MHLW clearance can cut your registration timeline in half. We will walk through a real-world case study of a U.S. company that successfully used this pathway, highlighting the critical documents and local requirements they needed to succeed. **This episode's key questions:** - What is the number one mistake foreign companies make when classifying their AI medical device for COFEPRIS? - How can your existing FDA clearance reduce your Mexico market entry timeline from over a year to just a few months? - Why is a Mexican Registration Holder (MRH) legally mandatory before you even submit your application? - What are the specific translation and labeling requirements that COFEPRIS strictly enforces? - How does the risk classification for a software-only device work without a physical component? - What common post-market surveillance duties for AI devices in Mexico often go overlooked? - Are there hidden fees in the COFEPRIS registration process that can surprise foreign applicants? Pure Global offers end-to-end regulatory consulting solutions for MedTech and IVD companies, combining local expertise with advanced AI to streamline global market access. If you're looking to enter the complex but rewarding Mexican market, let our experts guide your strategy. Contact us at info@pureglobal.com or visit https://pureglobal.com/ for more information.

This episode of LATAM MedTech Insights dives deep into the complex world of clinical data requirements for Software as a Medical Device (SaMD) seeking approval from Brazil's regulatory body, ANVISA. We unpack the critical regulation RDC 657/2022 and explain how ANVISA's risk-based classification system directly dictates the level of clinical evidence your company must provide. We explore the specific pathways for both low-risk and high-risk SaMD. Learn what kind of evidence can be used for simpler devices and understand the rigorous demands for more complex, high-impact software. We highlight common pitfalls and strategic considerations that can make or break your market entry into one of LATAM's most vital healthcare markets. A real-world scenario: Imagine your company has an AI diagnostic tool with successful FDA clearance based on US clinical trials. You're ready to launch in Brazil, but ANVISA puts your application on hold. They are questioning whether your data, collected from a predominantly Caucasian population, is valid for the ethnically diverse population of Brazil. Your launch is now delayed, and you face the unexpected cost of running a local validation study. Key Takeaways: * How does ANVISA's four-tier risk classification for SaMD directly impact your clinical data strategy? * Is your existing clinical data from the US or EU automatically sufficient for a Brazilian submission? * For low-risk SaMD, what are the alternatives to conducting a full clinical trial? * Why might ANVISA challenge world-class clinical data based on patient demographics? * What is a Brazil Registration Holder (BRH), and why is it a non-negotiable requirement for market access? * Under what specific circumstances is a dedicated, local clinical trial absolutely necessary for your SaMD? * How can you effectively leverage data from "equivalent devices" to strengthen your ANVISA submission? * What are the most common documentation and translation mistakes that lead to delays? Navigating the specifics of ANVISA's requirements can be overwhelming. At Pure Global, we provide end-to-end regulatory consulting for MedTech and IVD companies, combining deep local expertise in Brazil with advanced AI tools to streamline your path to market. From regulatory strategy and technical dossier submission to acting as your official Brazil Registration Holder, we manage the complexities so you can focus on growth. Contact us at info@pureglobal.com or visit https://pureglobal.com/ to streamline your market access to Brazil and beyond.

This episode of LATAM MedTech Insights dives into a critical question for innovators: How does Argentina's regulatory authority, ANMAT, handle artificial intelligence and machine learning in medical devices? We cut through the ambiguity to reveal that while there isn't a specific AI-only regulation, these products are actively regulated under the existing robust framework for Software as a Medical Device (SaMD). We explore the practical steps for registering an AI-powered device in Argentina, from the crucial risk classification process to the detailed requirements for your technical dossier. Using the example of an AI tool for diagnostic imaging, we illustrate the challenges and necessities, such as providing extensive algorithm validation data and the mandatory appointment of a local Argentina Registration Holder. This episode provides a clear roadmap for companies looking to enter this key LATAM market with cutting-edge technology. Key Takeaways: * What is the current official stance of ANMAT on regulating AI-specific medical devices? * How does Argentina's four-tier risk classification system apply to Software as a Medical Device? * What are the essential components of a technical dossier for an AI algorithm submitted to ANMAT? * Why is appointing an Argentina Registration Holder a non-negotiable step for foreign manufacturers? * What is the role of the IMDRF in shaping the future of AI medical device regulation in Argentina? * How can you prove the safety and efficacy of a "black box" machine learning algorithm to regulators? * What are the most common pitfalls to avoid when submitting an advanced software device for approval in Argentina? At Pure Global, we specialize in demystifying complex regulatory landscapes. We offer end-to-end solutions for MedTech and IVD companies, combining local expertise in over 30 markets with advanced AI tools to streamline your global market access. Let us be your local representative and strategic partner in Latin America and beyond. Contact us at info@pureglobal.com or visit https://pureglobal.com/ to learn more.

Last week, Brazil's regulatory agency, ANVISA, unveiled a groundbreaking 2025 plan to tackle its notorious medical device approval backlogs. The initiative, named "AnvisAI," leverages artificial intelligence to create an automated fast-track system for lower-risk devices, aiming to cut review times by more than half and reshape the market access landscape. This move signals a major shift, potentially transforming Brazil from one of the most challenging LATAM markets into a hub for MedTech innovation. This episode unpacks the details of the AnvisAI project, exploring what it means for manufacturers' regulatory strategies and the immediate opportunities it creates for faster market entry. We explore a critical case study: Imagine launching an innovative Software as a Medical Device (SaMD) and facing a 24-month approval delay, tying up capital and stalling growth. ANVISA's new AI-driven pathway could slash that wait time to just a few months, completely changing the financial and strategic calculus for entering Brazil. Key Takeaways: 1. What exactly is the "AnvisAI" project and how will it re-classify devices for the new fast-track? 2. Which specific device classes stand to benefit the most from automated approvals? 3. What are the hidden data and documentation requirements for submissions to the new AI system? 4. How does this decision position Brazil against other LATAM markets like Mexico and Colombia? 5. What are the immediate actions MedTech companies should take to adapt their registration strategy? 6. Will this new system require changes to post-market surveillance and vigilance reporting? 7. How does this initiative align with Brazil's broader National AI Strategy? Navigating Brazil's rapidly evolving regulatory landscape requires local expertise and advanced technological tools. At Pure Global, we offer end-to-end regulatory consulting solutions, combining on-the-ground experts in Brazil with proprietary AI tools to streamline your market access. From regulatory strategy and dossier preparation to acting as your local representative, we help you leverage these new opportunities for faster growth. To learn how we can accelerate your entry into the Brazilian market, contact us at info@pureglobal.com or visit https://pureglobal.com/.

As Colombia's healthcare market embraces digital transformation, understanding the regulatory pathway for Software as a Medical Device (SaMD) is crucial for innovators. This episode of LATAM MedTech Insights demystifies the INVIMA registration process, revealing that SaMD is not regulated under a separate framework, but through the country's existing medical device decrees. We provide a clear, step-by-step guide for manufacturers looking to enter this promising market. We break down the essential requirements, from the critical first step of risk classification to the mandatory appointment of a local legal representative. We detail the specific documentation needed for your technical dossier, including software validation, cybersecurity measures, and the crucial Certificate of Free Sale. Learn why a simple translation of your documents isn't enough and how to avoid the common pitfalls that can lead to significant delays and rejections from INVIMA. A US-based startup with an FDA-cleared AI diagnostic tool learned this the hard way. They assumed their existing documentation would suffice for their INVIMA submission but faced a nine-month delay. The reason? Their risk analysis failed to address specific patient data privacy concerns relevant to Colombian law, and their software validation data was presented in a format that was unfamiliar to the INVIMA reviewer, leading to a cascade of questions they were unprepared to answer. This costly delay could have been avoided with localized regulatory expertise. What You'll Learn: 1. Why is there no dedicated "SaMD" regulation in Colombia, and what does that mean for your submission? 2. What is the single most important decision you'll make before starting your INVIMA application? 3. Do you need a physical office in Colombia to register your software device? 4. How crucial is a Certificate of Free Sale from your home country for the approval process? 5. What specific software validation documents does INVIMA expect to see in your technical file? 6. Beyond simple translation, what localization details are critical for your labeling and instructions for use? 7. What is the most common and costly mistake that leads to long delays in the INVIMA review process? 8. How do cybersecurity considerations play a role in the Colombian registration of SaMD? At Pure Global, we specialize in transforming these complex regulatory challenges into clear market access strategies. We offer end-to-end solutions for MedTech and IVD companies, combining local expertise in over 30 markets with advanced AI and data tools to streamline your global expansion. From initial strategy to post-market surveillance, our team acts as your local representative to ensure your innovation reaches the market efficiently. Contact us to learn more at info@pureglobal.com or visit our website at https://pureglobal.com/.

In this episode of LATAM MedTech Insights, we explore the significant regulatory shift in Mexico concerning AI-powered medical software. Mexico's health authority, COFEPRIS, has updated its framework, moving away from treating software as a simple accessory to classifying it as a regulated medical device in its own right. This change is crucial for any MedTech company aiming to penetrate the vibrant Mexican market. We break down the new risk-based classification system—Class I, II, and III—and discuss how the intended use of your AI software determines its regulatory pathway. This episode provides essential information for developers and manufacturers, ensuring they understand the new rules of engagement to avoid costly delays and rejections. Case Study Spotlight: Imagine spending years developing a revolutionary AI tool that predicts cardiac risk from a selfie, only to have your market entry blocked by regulatory confusion. We examine the success story of Medsi AI, a company that successfully navigated the new COFEPRIS guidelines to get their AI-powered diagnostic platform approved as a Class II medical device, setting a vital precedent for the industry. Key Takeaways: - Why did COFEPRIS fundamentally change its regulations for Software as a Medical Device (SaMD)? - What are the specific criteria for Class I, II, and III risk classifications in Mexico? - How does my AI software's intended use directly impact its classification and submission requirements? - What key documentation was crucial for Medsi AI to secure its Class II approval? - Can I leverage my existing FDA or CE marking for an expedited review with COFEPRIS? - What are the most common pitfalls to avoid when submitting an AI SaMD application in Mexico? - How will this regulatory shift impact the future of digital health innovation in Latin America? Navigating the complex regulatory landscape of Latin America is our expertise. Pure Global offers end-to-end regulatory consulting solutions for MedTech and IVD companies, combining local expertise with advanced AI to streamline your global market access. For a clear and efficient pathway into markets like Mexico, contact us at info@pureglobal.com or visit https://pureglobal.com/.

This week on LATAM MedTech Insights, we demystify the regulatory maze of Brazil's ANVISA for companies developing AI and Software as a Medical Device (SaMD). As the largest market in Latin America, Brazil presents a massive opportunity, but its regulatory agency, ANVISA, has specific and stringent requirements that can stall market entry if you're unprepared. We explore the cornerstone regulation, RDC 657/2022, and how it interacts with the broader medical device framework. We break down the crucial four-tier risk classification system and explain how it dictates your entire path to market, from a simple notification for low-risk software to a full, complex registration for high-risk AI-driven diagnostics. Imagine your AI diagnostic tool, already successful in Europe with a CE mark, is ready for the Brazilian market. You begin the process, only to be stalled for months by unexpected demands for algorithm validation data, cybersecurity protocols, and the non-negotiable requirement for a local Brazil Registration Holder. This common pitfall can cost you valuable time, resources, and your first-mover advantage in a competitive landscape. Key Questions from this Episode: - What is the single most important ANVISA regulation you must know for SaMD in Brazil? - How does ANVISA classify the risk of your AI-powered medical software, and why is this the most critical step? - Does your low-risk SaMD need a full registration (*registro*) or a simpler notification (*notificação*)? - What specific documentation is required for high-risk AI devices that differs from traditional hardware? - Why is a Brazil Registration Holder (BRH) an absolute necessity for market entry? - How does ANVISA scrutinize the datasets used to train your machine learning algorithms? - What are ANVISA's expectations for post-market surveillance of adaptive AI that learns over time? - Can you leverage existing international approvals like a CE mark or FDA clearance to speed up your Brazilian submission? At Pure Global, we specialize in transforming these regulatory hurdles into strategic advantages. We offer end-to-end solutions, from developing your ANVISA submission strategy and compiling technical dossiers to acting as your local Brazil Registration Holder. Our blend of local expertise and advanced AI tools streamlines your path to market access across Latin America. Don't let regulatory complexity be a barrier to entry. Contact us at info@pureglobal.com or visit https://pureglobal.com/ to learn how we can accelerate your growth.

This episode of LATAM MedTech Insights tackles a critical question for manufacturers entering Brazil: Is a Good Manufacturing Practice (GMP) certificate really required for low-risk, Class I medical devices? We explore the common misconceptions surrounding ANVISA's RDC 751/2022 regulation and the simplified *notificação* registration pathway. Many companies assume the lack of an upfront certificate submission means compliance is optional. This can be a costly mistake. We reveal how ANVISA's post-market surveillance can place your market access at risk if you're not prepared, and discuss how programs like MDSAP can be a strategic asset for demonstrating compliance. **A Case Study in Risk:** Imagine your startup's Class I device is successfully launched in Brazil via the "easy" *notificação* route. Six months later, ANVISA announces a surprise inspection of your facility. Are you confident your Quality Management System is fully B-GMP compliant right now? If not, you face immediate product withdrawal, fines, and reputational damage. This episode tells you how to avoid that scenario. **Key Takeaways From This Episode:** - Do all device classes truly need a B-GMP certificate before registering in Brazil? - What is the crucial difference between compliance and submission under RDC 751/2022? - Why can the simplified *notificação* pathway for Class I devices become a regulatory trap? - How can a post-market surveillance audit jeopardize your entire Brazilian market presence? - What is the one program that can significantly streamline your ANVISA compliance process? - Is your Quality Management System truly ready for an unannounced ANVISA inspection today? - What is the real role of the Medical Device Single Audit Program (MDSAP) in Brazil? Pure Global offers end-to-end regulatory consulting solutions for MedTech and IVD companies, combining local expertise with advanced AI to streamline global market access. We act as your local representative, develop regulatory strategy, and ensure ongoing compliance in over 30 markets, including Brazil. Don't let regulatory surprises derail your expansion. Contact us at info@pureglobal.com or visit https://pureglobal.com/ to learn how we can secure your market access.